Summary of Key Points
Vicarious Surgical, an American surgical robotics company that once received investment from giants like Bill Gates and Jerry Yang and was compared to the Da Vinci robot, went bankrupt due to significant delays in product development and depletion of funds. The company, which originated from the scientific fiction ideas of MIT students, raised over 2 billion yuan through funding and listed on the NASDAQ, but its technology proved too idealistic (such as a complex robotic arm structure that made mass production difficult and limited clinical实用性), leading to its collapse just three years after listing. This case highlights the common challenges in the embodied intelligence industry: attractive concepts that are hard to implement, rapid capital consumption, and lack of revenue, posing a warning for the booming robotics sector.
I. The Former “Star Player”: From Science Fiction Dreams to Investment from Big Names
Vicarious’ story began in 2014 when two MIT mechanical engineering students were inspired by the science fiction movie *The Martian*. They wanted to turn the idea of a doctor being miniaturized and inserted into a patient for surgery into reality. The team had a strong technical background, with co-founders who were former engineers at Apple specializing in miniaturization design, and they also enlisted a surgeon as a consultant. Their product concept was impressive: a micro-robot that could enter the abdominal cavity through an incision less than 1.5 centimeters in size, with nine degrees of freedom (two more than the Da Vinci robot), allowing doctors to control the robotic arm via a VR headset for a immersive experience. This idea attracted significant investment from Bill Gates, former Google CEO Eric Schmidt, and Jerry Yang. Vicarious went public through a SPAC in 2021, reaching a market value of over $1.2 billion and was honored as one of *Time* magazine’s Best Inventions of the Year, as well as receiving FDA approval for its breakthrough device.
II. Why Did It Fail? Delays in Development and Exhaustion of Funds
Listing was Vicarious’ last highlight. The company had planned to start clinical trials in 2024 and submit for FDA approval in 2025, but the engineering challenges were much greater than expected, leading to repeated delays. For a revenue-generating startup, such promises became increasingly untrustworthy. By 2023, its market value had dropped by 90%, and it received a delisting warning; in 2024, it was forced to delist from the NASDAQ due to a market value of less than $15 million. More critically, the company ran out of funds. Despite raising a total of 2 billion yuan, it incurred losses of 766 million yuan between 2024 and 2025, with only $3.7 million remaining by March 2025—not even enough to cover its monthly expenses. With no new funding and no buyers willing to acquire the company, it had no choice but to file for bankruptcy, resulting in almost total losses for its shareholders.
III. Technology That Was Too “Idealistic”: Beautiful PPTs Don’t Translate into Reality
The root of Vicarious’ technical problems lay in its over-ambitious approach that ignored practical realities:
1. Complicated Robotic Arm Design: To mimic the flexibility of a human hand, they used a decoupled drive system, which resulted in a structure as complex as a Swiss watch, with extremely low production yields and failing to meet FDA standards.
2. Lack of Practical Functions: They designed only two robotic arms for small incisions, but many surgeries require multiple instruments; these two arms were insufficient for practical use.
3. VR Overpromise: The VR headset, while impressive, caused fatigue in doctors and was less efficient than traditional methods.
The team’s engineering focus was also flawed: they focused on achieving impressive technical specifications (such as more degrees of freedom) without considering the practical barriers to FDA approval and hospital adoption—both of which require time and funding, which they significantly underestimated.
IV. A Warning for the Embodied Intelligence Industry: Behind the Hype, There Are Serious Challenges
Vicarious is not an isolated case. Last year, Silicon Valley’s humanoid robotics company K-Scale Labs went bankrupt due to financial difficulties, and iRobot, the pioneer of robotic vacuum cleaners, also filed for bankruptcy. The embodied intelligence sector may seem promising (with substantial funding and high valuations), but it faces significant issues:
- Good-looking Demos, No Sales: Most robots are only displayed in laboratories or science museums; few can actually perform practical tasks. Industrial robots cost hundreds of thousands of dollars, and companies take four to five years to break even. Home robots have a 12.4% success rate at performing household chores, making them practically useless.
- Rapid Capital Consumption with No Revenue: The industry is still in its early stages, and few companies are profitable, relying entirely on funding to survive. A downturn in the capital market (e.g., rising interest rates) could lead to a funding crunch and company failures.
- **From a “League” to an “Elimination Round”: Early-stage startups can easily secure funding, but now the focus shifts to product development and commercialization. Companies must either have enough cash to turn a profit or create products that solve real problems; otherwise, they will be eliminated.
In summary, the embodied intelligence industry is a long-term endeavor that cannot rely solely on exciting concepts. It’s essential to address practical challenges in specific use cases (such as industrial processes or household tasks) and gradually improve products through iteration. Otherwise, companies like Vicarious will end up as a cautionary tale.